BY Linda Gilchriest

Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers have found.

A team led by author Emma Holliday, M.D., assistant professor of Radiation Oncology, published its research this month in JAMA Oncology, reporting that of 598 Phase III cancer studies published between 2003 and 2018, only 107, or 17.9 percent, had female corresponding authors.<...

A study by MD Anderson researchers of 598 phase III clinical trials showed only 17.9% of lead investigators were women.